ImmunityBio registers Phase 2a trial of NAI in sepsis with persistent lymphopenia

This week's notable item is a newly registered trial from ImmunityBio.

• ImmunityBio has registered a Phase 2a, randomized, double-blind, placebo-controlled trial (NCT07783789) evaluating nogapendekin alfa inbakicept (NAI) plus standard of care compared to standard of care alone in critically ill adults with sepsis and persistent lymphopenia.¹ The study is not yet recruiting, with an estimated enrollment of approximately 50 participants randomized in a 1:1 ratio.¹ It includes a safety run-in of the first 10 randomized participants, split roughly evenly between arms, with data reviewed by a safety committee or DSMB before the remaining participants are enrolled.¹ The primary outcome is titled "28-day all-cause mortality rate," measured from Day 1, the first NAI dose, through Day 28.¹